Premarket Approval (PMA) from the US Food and Drug Administration (FDA) has been granted for the VASCADE MVP Venous Vascular Closure System (Cardiva Medical). VASCADE MVP is the first and only vascular closure system designed and labelled specifically for multi-site venous closure—for 6–12 French inner diameter sheaths. This access site approach and size range is the standard in electrophysiology procedures such as cardiac ablation and left atrial appendage closure.
The approval is based on results of the AMBULATE pivotal trial, a 204-patient, 13-site randomised, controlled study of the VASCADE MVP System compared to standard manual compression following cardiac ablation. The study showed significant improvements in time to ambulation, total post-procedure time and time-to-discharge eligibility, as well as improved patient satisfaction scores and reduced use of opioid pain medications.
Results of the trial were presented at the 2018 American Heart Association Scientific Sessions (AHA; 10–12 November, Chicago, USA) by Andrea Natale, co-principal investigator and executive medical director, Texas Cardiac Arrhythmia Institute in Austin, USA.
VASCADE MVP uses a simple and proprietary delivery system to place a collagen patch on the outside of each vessel puncture site following completion of the procedure. Nothing is left behind inside the vessel, and the collagen outside the vessel wall is resorbed in a short period of time enabling reaccess for future procedures.
“We are at the dawn of a new era now for electrophysiology procedures with this trailblazing technology,” said Suneet Mittal, director of electrophysiology and medical director of The Snyder Center for Comprehensive Atrial Fibrillation at The Valley Hospital in Ridgewood, USA. “The improvements we have seen in both patient satisfaction and more efficient hospital workflow make this one of those rare new technologies that produces benefits for all stakeholders.”
